tp receptor

TP receptor antagonist-1 (compound 7m) serves as an antagonist for the thromboxane A2 receptor (TP receptor), exhibiting IC50 values of 9.46 μM for TPa and 8.49 μM for TPb. It is utilized in the study of cardiovascular diseases [1].

TP Receptor Antagonist-2 (example 7n), a thromboxane A2 receptor (TP receptor) antagonist, exhibits inhibitory activity with IC50 values of 5.64 μM for TPα and 5.27 μM for TPβ. It effectively inhibits platelet aggregation [1].

Laropiprant (MK-0524) is a potent and selective antagonist of prostaglandin D2 (PGD2) receptor (DP) such as and DP/DP1 receptor(Ki = 0.57 nM) and TP Receptor(Ki = 2.95 nM).

L 888607 is an effective and selective CRTH2 agonist (Ki: 0.8 nM).

L 888607 Racemate is a selective antagonist of the prostaglandin D2 receptor subtype 1 (DP1) with Ki values of 132 nM and 17 nM for DP1 and the thromboxane A2 receptor (TP), respectively.

SC 51089 is a selective prostaglandin receptor PGE2 antagonist with selectivity for prostaglandin receptor subtypes and antinociceptive activity that improves motor deficits and rescues memory decline in the Huntington's disease R6/1 mouse model .

Treprostinil (Orenitram) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).

Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).

Laropiprant sodium is a potent and selective DP receptor antagonist with Ki values of 0.57 nM (TP receptors) and 2.95 nM (DP receptors).

SC 51089 free base is a selective antagonist of the prostaglandin E2 EP1 receptor, demonstrating neuroprotective activity. It exhibits binding affinities (Kis) of 1.3 μM for EP1, 11.2 μM for TP, 17.5 μM for EP3, and 61.1 μM for FP receptors.

Prostaglandin J2 (PGJ2), a derivative of Prostaglandin D2 (PGD2), serves as a potent agonist for PGD2 receptors (DP), exhibiting affinity constants (K i) of 0.9 nM and 6.6 nM for hDP and hCRTH2 receptors, respectively. It activates cyclic AMP production with an EC50 of 1.2 nM, induces oxidative stress, neuronal apoptosis, and promotes the accumulation of ubiquitinated (Ub) proteins. Notably, PGJ2's neurotoxic properties are implicated in the progression of neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD) [1] [2] [3] [4].

MK-7246 is a potent and specific CRTH2 antagonist (Ki: 2.5 nM).

Seratrodast (ABT-001) (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor antagonist developed as an anti-asthmatic drug and attained marketing qualification in Japan in 1997.

KP496 is a selective, dual antagonist for the Thromboxane A2 receptor (TP) and the Leukotriene D4 receptor (cysLT1).

GW627368 (GW 627368X)X is a novel, potent and selective antagonist of prostanoid EP4 receptor.

Dubermatinib (TP0903) is a potent and selective Axl kinase inhibitor.

U-46619 Glycine methyl ester has been modified at its C-1 position, uniquely altering its binding properties with the TP receptor or any PGH2 metabolic enzymes. U-46619 functions as a stable analog of the endoperoxide PGH2 and acts as an agonist of the TP receptor. It induces changes in platelet shape, promotes vascular smooth muscle aggregation, and contraction. This compound is useful for studying its inhibitory effects on various enzymes involved in the arachidonic acid metabolism pathway. Additionally, U-46619 Glycine methyl ester serves as a lipophilic prodrug form of U-46619, affecting its distribution and pharmacokinetic characteristics.

TP003 is a novel non-selective GABAA receptor benzodiazepine site agonist with affinity for α1β2gam2, α2β3gam2, α3β3gam2, α5β2gam2, EC50 of 20.3, 10.6, 3.24, 5.64 nM, respectively. TP003 has antianxiety and partial anticonvulsant activity via the α2GABAA receptor.

Synthetic pentapeptide corresponding to the amino acids 32-36 of thymopoietin and exhibiting the full biological activity of the natural hormone. Thymopentin (TP5) is an immunomodulator which has been studied for possible use in the treatment of rheumatoid arthritis, AIDS, and other primary immunodeficiencies.

RS 61756-007 is a selective thromboxane receptor (TP) agonist.

ICI 192605 is a potent thromboxane A2 receptor (TP receptor) antagonist.

R-82913 is a RNA-directed DNA polymerase inhibitor. R 82913 reduce 5-HT2 receptor-mediated DOI-head-shakes in mice. R82913 inhibited the replication of thirteen different strains of HIV-1 in CEM cells with a median IC50 of 0.15 microM. R82913 was 20-fold

TP-680 is a antagonist of cholecystokininA receptor.

I-BOP is an agonist (KD=0.61 nM) at the thromboxane A2 receptor (TP). I-BOP promotes cell proliferation by activating the PI3K pathway in vascular smooth muscle.